118 related articles for article (PubMed ID: 3840612)
1. Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF.
Roila F; Minotti V; Ballatori E; Basurto C; Tonato M
Tumori; 1985 Oct; 71(5):455-8. PubMed ID: 3840612
[TBL] [Abstract][Full Text] [Related]
2. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D
Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
[TBL] [Abstract][Full Text] [Related]
3. The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
Campora E; Chiara S; Bruzzi P; Scarsi P; Rosso R
Tumori; 1985 Oct; 71(5):459-62. PubMed ID: 3904102
[TBL] [Abstract][Full Text] [Related]
4. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
[TBL] [Abstract][Full Text] [Related]
5. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Gez E; Warner-Efraty E; Ben-Yosef R; Ben-Baruch N; Yitzhaki N; Uziely B; Brufman G; Biran S
Oncology; 1987; 44(4):237-9. PubMed ID: 3614813
[TBL] [Abstract][Full Text] [Related]
6. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
Gez E; Sulkes A; Ochayon L; Gera C; Nathan S; Cass Y; Rubello E; Biran S
J Chemother; 1989 Dec; 1(6):365-8. PubMed ID: 2693621
[TBL] [Abstract][Full Text] [Related]
7. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
8. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Roila F; Tonato M; Basurto C; Minotti V; Ballatori E; del Favero A
Eur J Cancer Clin Oncol; 1987 Jun; 23(6):615-7. PubMed ID: 3308477
[TBL] [Abstract][Full Text] [Related]
9. An audit of antiemetic use with CMF chemotherapy.
Brown RS; Brown TK; Hoare D; Gaze MN
Clin Oncol (R Coll Radiol); 1998; 10(5):313-7. PubMed ID: 9848332
[TBL] [Abstract][Full Text] [Related]
10. High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
Gez E; Goodman S; Isacson R; Gerra C; Sulkes A
Oncology; 1986; 43(3):173-5. PubMed ID: 3754627
[TBL] [Abstract][Full Text] [Related]
11. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
12. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
13. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
[TBL] [Abstract][Full Text] [Related]
14. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
Campora E; Oliva C; Mammoliti S; Cetto GL; Fosser V; Marangolo M; Rosso R
Breast Cancer Res Treat; 1991 Oct; 19(2):129-32. PubMed ID: 1836746
[TBL] [Abstract][Full Text] [Related]
15. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
[TBL] [Abstract][Full Text] [Related]
16. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, cross-over study comparing a levosulpiride-based and a metoclopramide-based combination in the prevention of ProMECE-CytaBOM-induced emesis.
Sabbatini R; Federico M; Baldini L; Barbieri F; Maiolo MT; Silingardi V
Haematologica; 1995; 80(5):416-20. PubMed ID: 8566881
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation.
Gilbert CJ; Ohly KV; Rosner G; Peters WP
Cancer; 1995 Dec; 76(11):2330-7. PubMed ID: 8635039
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide.
David M; Durand M; Chauvergne J; Mauriac L; Bui BN; Hoerni B
Cancer Treat Rep; 1984 Jun; 68(6):921-2. PubMed ID: 6547368
[No Abstract] [Full Text] [Related]
[Next] [New Search]
